The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Anas Younes: two practice-changing abstracts at ASH 2018
In this interview, Anas Younes, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the two abstracts that in his opinion are practice-changing in the areas of T-cell lymphoma and chronic lymphocytic leukemia (CLL), presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA. These are the ECHELON-2 (NCT01777152) clinical trial results, focusing on the use of brentuximab vedotin and CHP in peripheral T-cell lymphomas, and the data on the use of ibrutinib and rituximab for the frontline treatment of CLL.
